Compass Pathways Prices $150M Public Offering
Analysis based on 10 articles · First reported Feb 19, 2026 · Last updated Feb 19, 2026
The public offering by Compass Pathways is expected to provide significant capital for its clinical trials and commercial readiness, which could positively impact its stock performance. The involvement of major financial institutions as book-runners and managers indicates market confidence in the offering.
Compass Pathways plc announced the pricing of its public offering of 17.5 million American Depositary Shares (ADSs) at $8.00 per ADS, and pre-funded warrants for up to 1.25 million ADSs at $7.9999 per warrant. The offering is expected to generate gross proceeds of $150 million, which Compass Pathways intends to use for funding ongoing Phase 3 trials for COMP005 and COMP006, a Phase 2b/3 trial of COMP360 in PTSD, accelerating commercial readiness activities, and for general corporate purposes. The offering is anticipated to close around February 20, 2026. Jefferies Financial Group===Jefferies Group, Toronto-Dominion Bank===TD Cowen, Cantor Fitzgerald, and Stifel are acting as joint book-runners, with H.C. Wainwright & Co. as lead manager and LifeSci Capital as financial advisor. The securities are being offered pursuant to a shelf registration statement filed with the United States===United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard